Page 12 - Aurobindo Pharma

Aurobindo Pharma declines 6% on USFDA warning letter for Dayton facility

The company said it would engage with the regulator and would try to resolve the issue at the earliest

Stock recommendation by Prabhudas Lilladher: Buy Hindalco, Aurobindo Pharma

The RSI indicator for Hindalco Industries has recently indicated a decent rise to imply strength

Stock calls by Nilesh Jain of Anand Rathi: Buy Bharat Forge, L&T Infotech

The stock of Bharat Forge has formed a strong base and has started making a higher top and higher bottom formation on the daily chart

Aurobindo Pharma: Multiple growth triggers to improve Street sentiment

Rebound in injectable sales, multiple product launches, strong European outlook and reduction in net debt are key earning triggers

Nifty placed at a crucial juncture: Sameet Chavan of Angel Broking

If these levels are taken out, this will certainly negate the bearish stance and then the indies can head higher.

HDFC Bank, Infosys help Sensex settle 259 pts higher, Nifty ends at 11,605

All that happened in the markets today

Two pharma stocks that Ajit Mishra of Religare Broking is bullish on

All indicators point to a gradual rise in Aurobindo Pharma's stock from the 100 EMA support

CSIR collaborates with Aurobindo Pharma to develop Covid-19 vaccines

The Council of Scientific and Industrial Research (CSIR) and Aurobindo Pharma Limited on Tuesday announced a collaboration to develop vaccines for COVID-19.As per the release issued by the Centre for Cellular & Molecular Biology (CCMB), under the signed agreement between CSIR- CCMB and Aurobindo Pharma, Aurobindo will partner with CSIR for the development of several novel COVID-19 vaccines."Three CSIR labs namely CCMB Hyderabad, Institute of Medical Technology (IMTECH), Chandigarh and Indian Institute of Chemical Biology (IICB), Kolkata are developing vaccine candidates using different technology platforms. Aurobindo will undertake clinical development and commercialization of the vaccines," it said.Commenting on this partnership, Dr Shekhar C Mande, Director General, CSIR, said that "Joining of hands of premier CSIR labs with industry for the development of vaccines will amplify India's efforts in indigenous vaccine development and also help in preparedness for future ...

Aurobindo gears up for multiple Covid-19 vaccines, ties up with CSIR

Developing own candidate; to develop and make CSIR vaccine candiates

Aurobindo Pharma ties up with BIRAC to develop coronavirus vaccine

Aurobindo Pharma on Tuesday announced collaboration with the Biotechnology Industry Research Assistance Council (BIRAC), set up by the Department of Biotechnology for the development of Covid vaccine

Covid-19 vaccine: Aurobindo expects phase-I, II trials by end of 2020

The firm has earmarked $150-200 million towards capital expenditure during the current fiscal year

Strong US portfolio to drive revenue growth for Aurobindo Pharma

Margins expected to improve on product mix and volume growth

Benchmarks settle flat, Nifty ends at 11,300; Bharti Airtel slips over 2%

All that happened in the markets today

Aurobindo Pharma declines 4% despite 23% YoY jump in June quarter profit

Interim dividend of Rs 1.25 per equity share of Re 1 has been approved by the board for FY21

Weekly trading ideas by Religare Broking: Buy Bharti Airtel, Titan Company

TITAN, after the breakout from a consolidation range, is gradually inching higher while holding strongly above the support zone of the long term moving average( 200 EMA) on the daily chart

Overall fall in volatility giving comfort to the bulls: Nilesh Jain

The volatility index, IndiaVIX, fell by 5 per cent and ended at a 4-month low of 24.75 levels on Thursday

Aurobindo Pharma developing products to expand portfolio in US, EU markets

Currently, five products are under development, out of which the first two products would be filed towards the end of this year or early next year

Aurobindo Pharma plans to launch 50-60 products in US in FY21

On a constant currency basis, it increased by 26 per cent year-on-year to around $1.62 billion led by improvement in volumes and new product launches

Strong Q4 performance, debt reduction show Aurobindo Pharma in good health

Despite an over 150 per cent rise since March lows, the stock can see more gains

MARKET: Financials drag indices lower; Sensex dips 129 pts, Nifty holds 10K

All that happened in the markets today